For research teamsHelp me find a study
Back to all studies
RecruitingNCT07105111

Effectiveness of valbenazine in adults with tardive dyskinesia

This study is recruiting in the United States. It focuses on adults with tardive dyskinesia who remain symptomatic while receiving or after stopping a VMAT2 inhibitor.

Schizophrenia, Depression, ...DrugOver 18 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT07105111. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether Valbenazine may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Valbenazine, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in United States.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

The official record suggests in-person participation through a clinic, with sites including Neurocrine Clinical Site in Bryant, Neurocrine Clinical Site in Fountain Valley, and Neurocrine Clinical Site in Orange. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 29, 2025
Recruitment status
Recruiting
Estimated enrollment
Not clearly listed
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT07105111
Official title
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT07105111. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Valbenazine. Phase 4 studies usually happen after treatment approval, to monitor real-world use.

Do I need to want to stop or reduce tobacco use to participate?

The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Will I need to change, stop, or stabilize my current treatment?

The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Neurocrine Biosciences, which appears to be a biotech company. The listed contact or investigator is Neurocrine Biosciences, affiliated with Neurocrine Biosciences. Sponsor website: https://www.neurocrine.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.